JPH07502736A - 親水性巨大分子からなる骨格を有する作用物質含有固形物およびその調製法 - Google Patents

親水性巨大分子からなる骨格を有する作用物質含有固形物およびその調製法

Info

Publication number: JPH07502736A
Authority: JP; Japan
Prior art keywords: gelatin; mixture; active substance; substance; derivatives
Prior art date: 1992-01-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP5512079A

Other languages

English (en)

Japanese (ja)

Inventor

ブンデルリッヒ，イェンス−クリスティアン

シック，ウルスラ

ベリー，ユルゲン

フリーデンライッヒ　ユルゲン

Original Assignee

アルファテック−ファルマ　ゲゼルシャフト　ミット　ベシュレンクテル　ハフツング

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-01-17

Filing date

1993-01-18

Publication date

1995-03-23

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27435369&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JPH07502736(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1992-01-17 Priority claimed from DE4201173A external-priority patent/DE4201173C2/de

1992-01-17 Priority claimed from DE4201179A external-priority patent/DE4201179A1/de

1993-01-18 Application filed by アルファテック−ファルマ　ゲゼルシャフト　ミット　ベシュレンクテル　ハフツング filed Critical アルファテック−ファルマ　ゲゼルシャフト　ミット　ベシュレンクテル　ハフツング

1995-03-23 Publication of JPH07502736A publication Critical patent/JPH07502736A/ja

Status Pending legal-status Critical Current

Links

239000013543 active substance Substances 0.000 title claims description 74
239000007787 solid Substances 0.000 title claims description 45
229920002521 macromolecule Polymers 0.000 title claims description 34
238000002360 preparation method Methods 0.000 title claims description 29
239000008188 pellet Substances 0.000 claims description 111
239000008273 gelatin Substances 0.000 claims description 110
229920000159 gelatin Polymers 0.000 claims description 110
108010010803 Gelatin Proteins 0.000 claims description 107
235000019322 gelatine Nutrition 0.000 claims description 107
235000011852 gelatine desserts Nutrition 0.000 claims description 107
239000000203 mixture Substances 0.000 claims description 95
239000000126 substance Substances 0.000 claims description 94
238000000034 method Methods 0.000 claims description 62
239000011159 matrix material Substances 0.000 claims description 60
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 56
102000008186 Collagen Human genes 0.000 claims description 46
108010035532 Collagen Proteins 0.000 claims description 46
229920001436 collagen Polymers 0.000 claims description 46
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 41
239000000463 material Substances 0.000 claims description 34
239000007788 liquid Substances 0.000 claims description 32
239000003814 drug Substances 0.000 claims description 29
HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims description 26
229960001597 nifedipine Drugs 0.000 claims description 26
238000009472 formulation Methods 0.000 claims description 24
239000000843 powder Substances 0.000 claims description 24
PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 23
108010082495 Dietary Plant Proteins Proteins 0.000 claims description 22
238000004519 manufacturing process Methods 0.000 claims description 22
239000003795 chemical substances by application Substances 0.000 claims description 21
238000001035 drying Methods 0.000 claims description 20
229910052757 nitrogen Inorganic materials 0.000 claims description 20
230000008569 process Effects 0.000 claims description 20
-1 ethyl galactomannan Chemical compound 0.000 claims description 19
235000000346 sugar Nutrition 0.000 claims description 17
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 15
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 15
125000004925 dihydropyridyl group Chemical class N1(CC=CC=C1)* 0.000 claims description 15
239000002904 solvent Substances 0.000 claims description 15
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 14
229940079593 drug Drugs 0.000 claims description 14
229920000642 polymer Polymers 0.000 claims description 14
239000000600 sorbitol Substances 0.000 claims description 14
OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 claims description 13
102000016942 Elastin Human genes 0.000 claims description 13
108010014258 Elastin Proteins 0.000 claims description 13
229920002549 elastin Polymers 0.000 claims description 13
229920002307 Dextran Polymers 0.000 claims description 12
239000000499 gel Substances 0.000 claims description 12
WNLRTRBMVRJNCN-UHFFFAOYSA-N hexanedioic acid Natural products OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims description 12
239000004014 plasticizer Substances 0.000 claims description 12
239000002245 particle Substances 0.000 claims description 11
235000010443 alginic acid Nutrition 0.000 claims description 10
229920000615 alginic acid Polymers 0.000 claims description 10
229940085304 dihydropyridine derivative selective calcium channel blockers with mainly vascular effects Drugs 0.000 claims description 10
229920001282 polysaccharide Polymers 0.000 claims description 10
239000003531 protein hydrolysate Substances 0.000 claims description 10
229920000926 Galactomannan Polymers 0.000 claims description 9
238000009826 distribution Methods 0.000 claims description 9
239000007789 gas Substances 0.000 claims description 9
235000011187 glycerol Nutrition 0.000 claims description 9
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 8
229920001817 Agar Polymers 0.000 claims description 8
108090000790 Enzymes Proteins 0.000 claims description 8
102000004190 Enzymes Human genes 0.000 claims description 8
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 8
229920002125 Sokalan® Polymers 0.000 claims description 8
239000008272 agar Substances 0.000 claims description 8
235000010419 agar Nutrition 0.000 claims description 8
229940072056 alginate Drugs 0.000 claims description 8
229920002678 cellulose Polymers 0.000 claims description 8
239000001913 cellulose Substances 0.000 claims description 8
239000002537 cosmetic Substances 0.000 claims description 8
239000006185 dispersion Substances 0.000 claims description 8
239000001814 pectin Substances 0.000 claims description 8
235000010987 pectin Nutrition 0.000 claims description 8
229920001277 pectin Polymers 0.000 claims description 8
239000004584 polyacrylic acid Substances 0.000 claims description 8
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims description 8
229920000881 Modified starch Polymers 0.000 claims description 7
239000004368 Modified starch Substances 0.000 claims description 7
239000001361 adipic acid Substances 0.000 claims description 7
235000011037 adipic acid Nutrition 0.000 claims description 7
230000015572 biosynthetic process Effects 0.000 claims description 7
235000019426 modified starch Nutrition 0.000 claims description 7
229920000193 polymethacrylate Polymers 0.000 claims description 7
239000005017 polysaccharide Substances 0.000 claims description 7
229920002635 polyurethane Polymers 0.000 claims description 7
239000004814 polyurethane Substances 0.000 claims description 7
GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 claims description 6
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 6
241000416162 Astragalus gummifer Species 0.000 claims description 6
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 6
229920001353 Dextrin Polymers 0.000 claims description 6
239000004375 Dextrin Substances 0.000 claims description 6
229920000084 Gum arabic Polymers 0.000 claims description 6
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 6
239000004372 Polyvinyl alcohol Substances 0.000 claims description 6
229920002472 Starch Polymers 0.000 claims description 6
229920001615 Tragacanth Polymers 0.000 claims description 6
235000010489 acacia gum Nutrition 0.000 claims description 6
239000000205 acacia gum Substances 0.000 claims description 6
235000019425 dextrin Nutrition 0.000 claims description 6
239000000796 flavoring agent Substances 0.000 claims description 6
235000019634 flavors Nutrition 0.000 claims description 6
239000008101 lactose Substances 0.000 claims description 6
238000002844 melting Methods 0.000 claims description 6
230000008018 melting Effects 0.000 claims description 6
229920002451 polyvinyl alcohol Polymers 0.000 claims description 6
235000019698 starch Nutrition 0.000 claims description 6
239000008107 starch Substances 0.000 claims description 6
235000010487 tragacanth Nutrition 0.000 claims description 6
239000000196 tragacanth Substances 0.000 claims description 6
229940116362 tragacanth Drugs 0.000 claims description 6
229920001285 xanthan gum Polymers 0.000 claims description 6
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 5
PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 claims description 5
108010088751 Albumins Proteins 0.000 claims description 5
102000009027 Albumins Human genes 0.000 claims description 5
229920001661 Chitosan Polymers 0.000 claims description 5
229920002774 Maltodextrin Polymers 0.000 claims description 5
239000005913 Maltodextrin Substances 0.000 claims description 5
108010009736 Protein Hydrolysates Proteins 0.000 claims description 5
229920001577 copolymer Polymers 0.000 claims description 5
150000002191 fatty alcohols Chemical class 0.000 claims description 5
150000004676 glycans Chemical class 0.000 claims description 5
229940035034 maltodextrin Drugs 0.000 claims description 5
VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 claims description 5
239000003607 modifier Substances 0.000 claims description 5
229960000227 nisoldipine Drugs 0.000 claims description 5
229960005425 nitrendipine Drugs 0.000 claims description 5
150000003626 triacylglycerols Chemical class 0.000 claims description 5
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
239000002202 Polyethylene glycol Substances 0.000 claims description 4
239000008103 glucose Substances 0.000 claims description 4
239000001087 glyceryl triacetate Substances 0.000 claims description 4
235000013773 glyceryl triacetate Nutrition 0.000 claims description 4
230000036541 health Effects 0.000 claims description 4
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 4
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims description 4
235000010355 mannitol Nutrition 0.000 claims description 4
125000005397 methacrylic acid ester group Chemical group 0.000 claims description 4
229920001223 polyethylene glycol Polymers 0.000 claims description 4
239000001267 polyvinylpyrrolidone Substances 0.000 claims description 4
229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
239000012265 solid product Substances 0.000 claims description 4
239000006188 syrup Substances 0.000 claims description 4
235000020357 syrup Nutrition 0.000 claims description 4
229960002622 triacetin Drugs 0.000 claims description 4
239000002253 acid Substances 0.000 claims description 3
229920002301 cellulose acetate Polymers 0.000 claims description 3
235000013305 food Nutrition 0.000 claims description 3
239000004615 ingredient Substances 0.000 claims description 3
239000003094 microcapsule Substances 0.000 claims description 3
229920000728 polyester Polymers 0.000 claims description 3
230000002441 reversible effect Effects 0.000 claims description 3
230000000153 supplemental effect Effects 0.000 claims description 3
229920008712 Copo Polymers 0.000 claims description 2
150000001323 aldoses Chemical group 0.000 claims description 2
OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 claims description 2
239000011248 coating agent Substances 0.000 claims description 2
238000000576 coating method Methods 0.000 claims description 2
150000001875 compounds Chemical class 0.000 claims description 2
125000005456 glyceride group Chemical group 0.000 claims description 2
239000002088 nanocapsule Substances 0.000 claims description 2
XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims description 2
235000013311 vegetables Nutrition 0.000 claims description 2
239000011343 solid material Substances 0.000 claims 15
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 4
241000978776 Senegalia senegal Species 0.000 claims 3
JHPBZFOKBAGZBL-UHFFFAOYSA-N (3-hydroxy-2,2,4-trimethylpentyl) 2-methylprop-2-enoate Chemical compound CC(C)C(O)C(C)(C)COC(=O)C(C)=C JHPBZFOKBAGZBL-UHFFFAOYSA-N 0.000 claims 2
229920000623 Cellulose acetate phthalate Polymers 0.000 claims 2
239000004471 Glycine Substances 0.000 claims 2
239000004698 Polyethylene Substances 0.000 claims 2
239000000654 additive Substances 0.000 claims 2
229940081734 cellulose acetate phthalate Drugs 0.000 claims 2
229920000573 polyethylene Polymers 0.000 claims 2
WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 claims 1
206010011224 Cough Diseases 0.000 claims 1
229920000057 Mannan Polymers 0.000 claims 1
235000008331 Pinus X rigitaeda Nutrition 0.000 claims 1
235000011613 Pinus brutia Nutrition 0.000 claims 1
241000018646 Pinus brutia Species 0.000 claims 1
150000001336 alkenes Chemical class 0.000 claims 1
229940043350 citral Drugs 0.000 claims 1
230000000295 complement effect Effects 0.000 claims 1
239000013583 drug formulation Substances 0.000 claims 1
235000014105 formulated food Nutrition 0.000 claims 1
WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 claims 1
229940037525 nasal preparations Drugs 0.000 claims 1
JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 claims 1
PXDJXZJSCPSGGI-UHFFFAOYSA-N palmityl palmitate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 claims 1
239000008194 pharmaceutical composition Substances 0.000 claims 1
229920000058 polyacrylate Polymers 0.000 claims 1
230000003449 preventive effect Effects 0.000 claims 1
ZCUFMDLYAMJYST-UHFFFAOYSA-N thorium dioxide Chemical compound O=[Th]=O ZCUFMDLYAMJYST-UHFFFAOYSA-N 0.000 claims 1
229920002554 vinyl polymer Polymers 0.000 claims 1
239000000243 solution Substances 0.000 description 31
239000000047 product Substances 0.000 description 29
239000012907 medicinal substance Substances 0.000 description 26
239000008187 granular material Substances 0.000 description 24
239000003826 tablet Substances 0.000 description 14
238000010521 absorption reaction Methods 0.000 description 13
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 10
239000007903 gelatin capsule Substances 0.000 description 10
229960001680 ibuprofen Drugs 0.000 description 10
238000012545 processing Methods 0.000 description 10
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 8
239000002552 dosage form Substances 0.000 description 8
238000007710 freezing Methods 0.000 description 8
230000008014 freezing Effects 0.000 description 8
108090000765 processed proteins & peptides Proteins 0.000 description 8
239000008186 active pharmaceutical agent Substances 0.000 description 7
230000008901 benefit Effects 0.000 description 7
229940088679 drug related substance Drugs 0.000 description 7
229940088598 enzyme Drugs 0.000 description 7
210000002919 epithelial cell Anatomy 0.000 description 7
238000007654 immersion Methods 0.000 description 7
239000003960 organic solvent Substances 0.000 description 7
238000003756 stirring Methods 0.000 description 7
239000000227 bioadhesive Substances 0.000 description 6
230000008859 change Effects 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
239000012153 distilled water Substances 0.000 description 6
238000005755 formation reaction Methods 0.000 description 6
239000002609 medium Substances 0.000 description 6
102000004169 proteins and genes Human genes 0.000 description 6
108090000623 proteins and genes Proteins 0.000 description 6
241000894007 species Species 0.000 description 6
239000000725 suspension Substances 0.000 description 6
YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 5
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
102000003886 Glycoproteins Human genes 0.000 description 5
108090000288 Glycoproteins Proteins 0.000 description 5
238000004132 cross linking Methods 0.000 description 5
238000000354 decomposition reaction Methods 0.000 description 5
238000009792 diffusion process Methods 0.000 description 5
238000004090 dissolution Methods 0.000 description 5
239000000839 emulsion Substances 0.000 description 5
239000000945 filler Substances 0.000 description 5
238000005469 granulation Methods 0.000 description 5
230000003179 granulation Effects 0.000 description 5
238000000465 moulding Methods 0.000 description 5
238000005453 pelletization Methods 0.000 description 5
239000004094 surface-active agent Substances 0.000 description 5
230000008961 swelling Effects 0.000 description 5
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 4
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
229930006000 Sucrose Natural products 0.000 description 4
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
235000010323 ascorbic acid Nutrition 0.000 description 4
229960005070 ascorbic acid Drugs 0.000 description 4
239000011668 ascorbic acid Substances 0.000 description 4
230000004888 barrier function Effects 0.000 description 4
239000002775 capsule Substances 0.000 description 4
230000003111 delayed effect Effects 0.000 description 4
239000003995 emulsifying agent Substances 0.000 description 4
230000001804 emulsifying effect Effects 0.000 description 4
235000003599 food sweetener Nutrition 0.000 description 4
238000004108 freeze drying Methods 0.000 description 4
210000001035 gastrointestinal tract Anatomy 0.000 description 4
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 4
239000000787 lecithin Substances 0.000 description 4
235000010445 lecithin Nutrition 0.000 description 4
229940067606 lecithin Drugs 0.000 description 4
239000000419 plant extract Substances 0.000 description 4
102000004196 processed proteins & peptides Human genes 0.000 description 4
239000003381 stabilizer Substances 0.000 description 4
238000003860 storage Methods 0.000 description 4
229960004793 sucrose Drugs 0.000 description 4
239000003765 sweetening agent Substances 0.000 description 4
238000010257 thawing Methods 0.000 description 4
229940088594 vitamin Drugs 0.000 description 4
229930003231 vitamin Natural products 0.000 description 4
235000013343 vitamin Nutrition 0.000 description 4
239000011782 vitamin Substances 0.000 description 4
244000215068 Acacia senegal Species 0.000 description 3
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
229940127291 Calcium channel antagonist Drugs 0.000 description 3
229920000858 Cyclodextrin Polymers 0.000 description 3
229930195725 Mannitol Natural products 0.000 description 3
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
229960001138 acetylsalicylic acid Drugs 0.000 description 3
230000002378 acidificating effect Effects 0.000 description 3
230000009471 action Effects 0.000 description 3
239000012736 aqueous medium Substances 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
235000021466 carotenoid Nutrition 0.000 description 3
150000001747 carotenoids Chemical class 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
210000001072 colon Anatomy 0.000 description 3
239000008139 complexing agent Substances 0.000 description 3
229940097362 cyclodextrins Drugs 0.000 description 3
238000011161 development Methods 0.000 description 3
235000005911 diet Nutrition 0.000 description 3
235000019262 disodium citrate Nutrition 0.000 description 3
239000002526 disodium citrate Substances 0.000 description 3
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
229910000397 disodium phosphate Inorganic materials 0.000 description 3
235000019800 disodium phosphate Nutrition 0.000 description 3
CEYULKASIQJZGP-UHFFFAOYSA-L disodium;2-(carboxymethyl)-2-hydroxybutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O CEYULKASIQJZGP-UHFFFAOYSA-L 0.000 description 3
239000002270 dispersing agent Substances 0.000 description 3
239000002934 diuretic Substances 0.000 description 3
229940030606 diuretics Drugs 0.000 description 3
230000000694 effects Effects 0.000 description 3
230000002255 enzymatic effect Effects 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
238000011049 filling Methods 0.000 description 3
230000002496 gastric effect Effects 0.000 description 3
210000004051 gastric juice Anatomy 0.000 description 3
239000000594 mannitol Substances 0.000 description 3
239000003921 oil Substances 0.000 description 3
235000019198 oils Nutrition 0.000 description 3
238000001556 precipitation Methods 0.000 description 3
230000001681 protective effect Effects 0.000 description 3
230000000717 retained effect Effects 0.000 description 3
238000007493 shaping process Methods 0.000 description 3
239000001488 sodium phosphate Substances 0.000 description 3
210000002784 stomach Anatomy 0.000 description 3
239000005720 sucrose Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
238000012546 transfer Methods 0.000 description 3
230000007704 transition Effects 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
WCVOGSZTONGSQY-UHFFFAOYSA-N 2,4,6-trichloroanisole Chemical compound COC1=C(Cl)C=C(Cl)C=C1Cl WCVOGSZTONGSQY-UHFFFAOYSA-N 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
ZAKOWWREFLAJOT-UHFFFAOYSA-N DL-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 description 2
241000196324 Embryophyta Species 0.000 description 2
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
229920002306 Glycocalyx Polymers 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
235000007688 Lycopersicon esculentum Nutrition 0.000 description 2
206010034972 Photosensitivity reaction Diseases 0.000 description 2
240000003768 Solanum lycopersicum Species 0.000 description 2
239000000150 Sympathomimetic Substances 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
230000002411 adverse Effects 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
229960003022 amoxicillin Drugs 0.000 description 2
LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 2
239000003416 antiarrhythmic agent Substances 0.000 description 2
159000000007 calcium salts Chemical class 0.000 description 2
239000012876 carrier material Substances 0.000 description 2
229940045110 chitosan Drugs 0.000 description 2
ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 2
229960001076 chlorpromazine Drugs 0.000 description 2
230000000112 colonic effect Effects 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
239000004020 conductor Substances 0.000 description 2
238000001816 cooling Methods 0.000 description 2
239000013078 crystal Substances 0.000 description 2
238000007872 degassing Methods 0.000 description 2
229960003957 dexamethasone Drugs 0.000 description 2
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
230000000378 dietary effect Effects 0.000 description 2
WDJUZGPOPHTGOT-XUDUSOBPSA-N digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 description 2
229960000648 digitoxin Drugs 0.000 description 2
229960004704 dihydroergotamine Drugs 0.000 description 2
HESHRHUZIWVEAJ-JGRZULCMSA-N dihydroergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C)C1=CC=CC=C1 HESHRHUZIWVEAJ-JGRZULCMSA-N 0.000 description 2
238000007922 dissolution test Methods 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
238000009501 film coating Methods 0.000 description 2
239000007888 film coating Substances 0.000 description 2
239000011521 glass Substances 0.000 description 2
210000004517 glycocalyx Anatomy 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
239000005556 hormone Substances 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
210000000936 intestine Anatomy 0.000 description 2
238000012423 maintenance Methods 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
239000000155 melt Substances 0.000 description 2
239000012528 membrane Substances 0.000 description 2
210000004379 membrane Anatomy 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
210000003097 mucus Anatomy 0.000 description 2
210000005036 nerve Anatomy 0.000 description 2
238000006386 neutralization reaction Methods 0.000 description 2
LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 2
XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
HCTVWSOKIJULET-LQDWTQKMSA-M phenoxymethylpenicillin potassium Chemical compound [K+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)COC1=CC=CC=C1 HCTVWSOKIJULET-LQDWTQKMSA-M 0.000 description 2
150000003904 phospholipids Chemical class 0.000 description 2
230000036211 photosensitivity Effects 0.000 description 2
230000004962 physiological condition Effects 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
229920005862 polyol Polymers 0.000 description 2
150000003077 polyols Chemical class 0.000 description 2
239000001103 potassium chloride Substances 0.000 description 2
235000011164 potassium chloride Nutrition 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
230000000541 pulsatile effect Effects 0.000 description 2
JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 2
229960001225 rifampicin Drugs 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
239000007921 spray Substances 0.000 description 2
239000000021 stimulant Substances 0.000 description 2
238000000859 sublimation Methods 0.000 description 2
230000008022 sublimation Effects 0.000 description 2
150000005846 sugar alcohols Chemical class 0.000 description 2
229940127230 sympathomimetic drug Drugs 0.000 description 2
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
230000032258 transport Effects 0.000 description 2
229960005486 vaccine Drugs 0.000 description 2
238000009834 vaporization Methods 0.000 description 2
230000008016 vaporization Effects 0.000 description 2
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 description 1
HAKRSIFCTAKBRD-TYFJVFSVSA-N (8s,9s,10r,13s,14s,17s)-17-acetyl-1-methoxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one Chemical compound C1C[C@@H]2[C@@]3(C)C(OC)CC(=O)C=C3CC[C@H]2[C@@H]2CC[C@H](C(C)=O)[C@]21C HAKRSIFCTAKBRD-TYFJVFSVSA-N 0.000 description 1
METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
RWNNRGBCWXOVAC-UHFFFAOYSA-N 1,4-bis[bis(aziridin-1-yl)phosphoryl]piperazine Chemical compound C1CN1P(N1CCN(CC1)P(=O)(N1CC1)N1CC1)(=O)N1CC1 RWNNRGBCWXOVAC-UHFFFAOYSA-N 0.000 description 1
BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
239000005541 ACE inhibitor Substances 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
244000016163 Allium sibiricum Species 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
102000055006 Calcitonin Human genes 0.000 description 1
108060001064 Calcitonin Proteins 0.000 description 1
229930186147 Cephalosporin Natural products 0.000 description 1
241000282994 Cervidae Species 0.000 description 1
JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
239000004971 Cross linker Substances 0.000 description 1
ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
102000016911 Deoxyribonucleases Human genes 0.000 description 1
108010053770 Deoxyribonucleases Proteins 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
240000001879 Digitalis lutea Species 0.000 description 1
241000255925 Diptera Species 0.000 description 1
108010061435 Enalapril Proteins 0.000 description 1
BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
102000004961 Furin Human genes 0.000 description 1
108090001126 Furin Proteins 0.000 description 1
XQLWNAFCTODIRK-UHFFFAOYSA-N Gallopamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC(OC)=C(OC)C(OC)=C1 XQLWNAFCTODIRK-UHFFFAOYSA-N 0.000 description 1
239000009429 Ginkgo biloba extract Substances 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
235000010469 Glycine max Nutrition 0.000 description 1
201000005569 Gout Diseases 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
241000546188 Hypericum Species 0.000 description 1
235000017309 Hypericum perforatum Nutrition 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
240000008415 Lactuca sativa Species 0.000 description 1
235000003228 Lactuca sativa Nutrition 0.000 description 1
OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
208000003926 Myelitis Diseases 0.000 description 1
HJMPSKKJHVWPBK-UHFFFAOYSA-N N-nitrososarcosine Chemical compound O=NN(C)CC(O)=O HJMPSKKJHVWPBK-UHFFFAOYSA-N 0.000 description 1
101710164303 N-succinylamino acid racemase Proteins 0.000 description 1
CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
229930182559 Natural dye Natural products 0.000 description 1
SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
229930195708 Penicillin V Natural products 0.000 description 1
206010057249 Phagocytosis Diseases 0.000 description 1
CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
239000004721 Polyphenylene oxide Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
108090000783 Renin Proteins 0.000 description 1
102100028255 Renin Human genes 0.000 description 1
244000000231 Sesamum indicum Species 0.000 description 1
235000003434 Sesamum indicum Nutrition 0.000 description 1
229920002334 Spandex Polymers 0.000 description 1
JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
102000000591 Tight Junction Proteins Human genes 0.000 description 1
108010002321 Tight Junction Proteins Proteins 0.000 description 1
FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 1
229940123445 Tricyclic antidepressant Drugs 0.000 description 1
235000021307 Triticum Nutrition 0.000 description 1
244000098338 Triticum aestivum Species 0.000 description 1
229930003427 Vitamin E Natural products 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
229960004308 acetylcysteine Drugs 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
229940087168 alpha tocopherol Drugs 0.000 description 1
229960002213 alprenolol Drugs 0.000 description 1
PAZJSJFMUHDSTF-UHFFFAOYSA-N alprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1CC=C PAZJSJFMUHDSTF-UHFFFAOYSA-N 0.000 description 1
DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
229960003805 amantadine Drugs 0.000 description 1
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000003474 anti-emetic effect Effects 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229940035678 anti-parkinson drug Drugs 0.000 description 1
230000002921 anti-spasmodic effect Effects 0.000 description 1
230000001362 anti-vertigo Effects 0.000 description 1
239000000924 antiasthmatic agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
239000002111 antiemetic agent Substances 0.000 description 1
229940125683 antiemetic agent Drugs 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
229940127088 antihypertensive drug Drugs 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
229940124575 antispasmodic agent Drugs 0.000 description 1
239000003699 antiulcer agent Substances 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
229960002274 atenolol Drugs 0.000 description 1
SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
229960002537 betamethasone Drugs 0.000 description 1
UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
235000013361 beverage Nutrition 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
239000011616 biotin Substances 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
229960003870 bromhexine Drugs 0.000 description 1
OJGDCBLYJGHCIH-UHFFFAOYSA-N bromhexine Chemical compound C1CCCCC1N(C)CC1=CC(Br)=CC(Br)=C1N OJGDCBLYJGHCIH-UHFFFAOYSA-N 0.000 description 1
229960000330 bupranolol Drugs 0.000 description 1
HQIRNZOQPUAHHV-UHFFFAOYSA-N bupranolol Chemical compound CC1=CC=C(Cl)C(OCC(O)CNC(C)(C)C)=C1 HQIRNZOQPUAHHV-UHFFFAOYSA-N 0.000 description 1
RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
229960001736 buprenorphine Drugs 0.000 description 1
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
229960004015 calcitonin Drugs 0.000 description 1
239000000480 calcium channel blocker Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
229960000830 captopril Drugs 0.000 description 1
FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 1
229960005361 cefaclor Drugs 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 1
229940124587 cephalosporin Drugs 0.000 description 1
150000001780 cephalosporins Chemical class 0.000 description 1
235000013339 cereals Nutrition 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
229960004022 clotrimazole Drugs 0.000 description 1
VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
235000012716 cod liver oil Nutrition 0.000 description 1
239000003026 cod liver oil Substances 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000005056 compaction Methods 0.000 description 1
238000007596 consolidation process Methods 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000010276 construction Methods 0.000 description 1
238000011109 contamination Methods 0.000 description 1
230000008602 contraction Effects 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
208000029078 coronary artery disease Diseases 0.000 description 1
239000006071 cream Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
238000004042 decolorization Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000003795 desorption Methods 0.000 description 1
229940109357 desoxyribonuclease Drugs 0.000 description 1
238000010586 diagram Methods 0.000 description 1
229960003529 diazepam Drugs 0.000 description 1
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
125000000664 diazo group Chemical group [N-]=[N+]=[*] 0.000 description 1
VLCINIKIVYNLPT-UHFFFAOYSA-J dicalcium;hydrogen phosphate Chemical compound [Ca+2].[Ca+2].OP(O)([O-])=O.[O-]P([O-])([O-])=O VLCINIKIVYNLPT-UHFFFAOYSA-J 0.000 description 1
230000037213 diet Effects 0.000 description 1
235000013681 dietary sucrose Nutrition 0.000 description 1
VQKLRVZQQYVIJW-UHFFFAOYSA-N dihydralazine Chemical compound C1=CC=C2C(NN)=NN=C(NN)C2=C1 VQKLRVZQQYVIJW-UHFFFAOYSA-N 0.000 description 1
229960002877 dihydralazine Drugs 0.000 description 1
229910001873 dinitrogen Inorganic materials 0.000 description 1
ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
229960000520 diphenhydramine Drugs 0.000 description 1
238000007598 dipping method Methods 0.000 description 1
229960003722 doxycycline Drugs 0.000 description 1
XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 1
239000008298 dragée Substances 0.000 description 1
230000035622 drinking Effects 0.000 description 1
229940072185 drug for treatment of tuberculosis Drugs 0.000 description 1
238000007908 dry granulation Methods 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
229960000873 enalapril Drugs 0.000 description 1
GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
206010015037 epilepsy Diseases 0.000 description 1
229960004943 ergotamine Drugs 0.000 description 1
OFKDAAIKGIBASY-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 description 1
XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 description 1
229960003276 erythromycin Drugs 0.000 description 1
229960002568 ethinylestradiol Drugs 0.000 description 1
235000008524 evening primrose extract Nutrition 0.000 description 1
239000010475 evening primrose oil Substances 0.000 description 1
229940089020 evening primrose oil Drugs 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
239000003172 expectorant agent Substances 0.000 description 1
239000000284 extract Substances 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
102000034240 fibrous proteins Human genes 0.000 description 1
108091005899 fibrous proteins Proteins 0.000 description 1
239000012467 final product Substances 0.000 description 1
230000009969 flowable effect Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
230000037406 food intake Effects 0.000 description 1
230000006870 function Effects 0.000 description 1
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
229960003883 furosemide Drugs 0.000 description 1
229960000457 gallopamil Drugs 0.000 description 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
239000010647 garlic oil Substances 0.000 description 1
210000001156 gastric mucosa Anatomy 0.000 description 1
229940068052 ginkgo biloba extract Drugs 0.000 description 1
235000020686 ginkgo biloba extract Nutrition 0.000 description 1
229960004580 glibenclamide Drugs 0.000 description 1
ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
235000012907 honey Nutrition 0.000 description 1
229960002003 hydrochlorothiazide Drugs 0.000 description 1
239000003326 hypnotic agent Substances 0.000 description 1
230000000147 hypnotic effect Effects 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
238000002513 implantation Methods 0.000 description 1
230000006872 improvement Effects 0.000 description 1
229960000905 indomethacin Drugs 0.000 description 1
230000006698 induction Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
239000012774 insulation material Substances 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
239000013067 intermediate product Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
239000002085 irritant Substances 0.000 description 1
231100000021 irritant Toxicity 0.000 description 1
230000007794 irritation Effects 0.000 description 1
DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
229960000991 ketoprofen Drugs 0.000 description 1
210000003127 knee Anatomy 0.000 description 1
210000002429 large intestine Anatomy 0.000 description 1
229960004502 levodopa Drugs 0.000 description 1
XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
229960005287 lincomycin Drugs 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
238000002690 local anesthesia Methods 0.000 description 1
239000003509 long acting drug Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
OJURWUUOVGOHJZ-UHFFFAOYSA-N methyl 2-[(2-acetyloxyphenyl)methyl-[2-[(2-acetyloxyphenyl)methyl-(2-methoxy-2-oxoethyl)amino]ethyl]amino]acetate Chemical compound C=1C=CC=C(OC(C)=O)C=1CN(CC(=O)OC)CCN(CC(=O)OC)CC1=CC=CC=C1OC(C)=O OJURWUUOVGOHJZ-UHFFFAOYSA-N 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
229960004584 methylprednisolone Drugs 0.000 description 1
229960004503 metoclopramide Drugs 0.000 description 1
TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
239000004530 micro-emulsion Substances 0.000 description 1
239000011707 mineral Substances 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
238000002156 mixing Methods 0.000 description 1
XLFWDASMENKTKL-UHFFFAOYSA-N molsidomine Chemical compound O1C(N=C([O-])OCC)=C[N+](N2CCOCC2)=N1 XLFWDASMENKTKL-UHFFFAOYSA-N 0.000 description 1
229960004027 molsidomine Drugs 0.000 description 1
229960005181 morphine Drugs 0.000 description 1
210000000214 mouth Anatomy 0.000 description 1
230000000510 mucolytic effect Effects 0.000 description 1
229940066491 mucolytics Drugs 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
229960000210 nalidixic acid Drugs 0.000 description 1
MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 1
239000002086 nanomaterial Substances 0.000 description 1
229960002009 naproxen Drugs 0.000 description 1
CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
239000000978 natural dye Substances 0.000 description 1
239000005445 natural material Substances 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
229960003512 nicotinic acid Drugs 0.000 description 1
235000001968 nicotinic acid Nutrition 0.000 description 1
239000011664 nicotinic acid Substances 0.000 description 1
150000002823 nitrates Chemical class 0.000 description 1
229910052756 noble gas Inorganic materials 0.000 description 1
150000002835 noble gases Chemical class 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
229960001180 norfloxacin Drugs 0.000 description 1
OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
101710125387 o-succinylbenzoate synthase Proteins 0.000 description 1
229960001699 ofloxacin Drugs 0.000 description 1
239000002674 ointment Substances 0.000 description 1
229920001542 oligosaccharide Polymers 0.000 description 1
150000002482 oligosaccharides Chemical class 0.000 description 1
235000020660 omega-3 fatty acid Nutrition 0.000 description 1
229940012843 omega-3 fatty acid Drugs 0.000 description 1
239000006014 omega-3 oil Substances 0.000 description 1
238000005457 optimization Methods 0.000 description 1
229940127017 oral antidiabetic Drugs 0.000 description 1
239000007968 orange flavor Substances 0.000 description 1
239000003002 pH adjusting agent Substances 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
238000012856 packing Methods 0.000 description 1
229960001789 papaverine Drugs 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
229940056367 penicillin v Drugs 0.000 description 1
VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 1
229960005301 pentazocine Drugs 0.000 description 1
230000008782 phagocytosis Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000012071 phase Substances 0.000 description 1
BPLBGHOLXOTWMN-MBNYWOFBSA-N phenoxymethylpenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 description 1
229960002036 phenytoin Drugs 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
239000000049 pigment Substances 0.000 description 1
239000003058 plasma substitute Substances 0.000 description 1
229940012957 plasmin Drugs 0.000 description 1
229920000570 polyether Polymers 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
229910001414 potassium ion Inorganic materials 0.000 description 1
FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
229960005205 prednisolone Drugs 0.000 description 1
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
229960004618 prednisone Drugs 0.000 description 1
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
238000004321 preservation Methods 0.000 description 1
238000003825 pressing Methods 0.000 description 1
229940043274 prophylactic drug Drugs 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
ZHNFLHYOFXQIOW-LPYZJUEESA-N quinine sulfate dihydrate Chemical compound [H+].[H+].O.O.[O-]S([O-])(=O)=O.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 ZHNFLHYOFXQIOW-LPYZJUEESA-N 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000009877 rendering Methods 0.000 description 1
230000000979 retarding effect Effects 0.000 description 1
238000010079 rubber tapping Methods 0.000 description 1
229960002052 salbutamol Drugs 0.000 description 1
239000010671 sandalwood oil Substances 0.000 description 1
239000003229 sclerosing agent Substances 0.000 description 1
239000000932 sedative agent Substances 0.000 description 1
229940125723 sedative agent Drugs 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000005245 sintering Methods 0.000 description 1
238000002791 soaking Methods 0.000 description 1
LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
229960002256 spironolactone Drugs 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000003270 steroid hormone Substances 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
108010013480 succinylated gelatin Proteins 0.000 description 1
229940007079 succinylated gelatin Drugs 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
239000013589 supplement Substances 0.000 description 1
230000009747 swallowing Effects 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
229960000278 theophylline Drugs 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
235000019157 thiamine Nutrition 0.000 description 1
KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
229960003495 thiamine Drugs 0.000 description 1
239000011721 thiamine Substances 0.000 description 1
210000001578 tight junction Anatomy 0.000 description 1
229960000984 tocofersolan Drugs 0.000 description 1
229940042585 tocopherol acetate Drugs 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
239000003204 tranquilizing agent Substances 0.000 description 1
230000002936 tranquilizing effect Effects 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000007723 transport mechanism Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
239000003029 tricyclic antidepressant agent Substances 0.000 description 1
229960001082 trimethoprim Drugs 0.000 description 1
IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
238000009827 uniform distribution Methods 0.000 description 1
229960001722 verapamil Drugs 0.000 description 1
238000012795 verification Methods 0.000 description 1
229940046009 vitamin E Drugs 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
239000002699 waste material Substances 0.000 description 1
239000002076 α-tocopherol Substances 0.000 description 1
235000004835 α-tocopherol Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0216—Solid or semisolid forms
- A61K8/022—Powders; Compacted Powders
- A61K8/0225—Granulated powders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1658—Proteins, e.g. albumin, gelatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Birds (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biotechnology (AREA)
Botany (AREA)
Microbiology (AREA)
Mycology (AREA)
Dermatology (AREA)
Medicinal Preparation (AREA)
Cosmetics (AREA)
Compositions Of Macromolecular Compounds (AREA)
Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Processes Of Treating Macromolecular Substances (AREA)
Fire-Extinguishing Compositions (AREA)
Treatments Of Macromolecular Shaped Articles (AREA)
Absorbent Articles And Supports Therefor (AREA)
Glanulating (AREA)

JP5512079A 1992-01-17 1993-01-18 親水性巨大分子からなる骨格を有する作用物質含有固形物およびその調製法 Pending JPH07502736A (ja)

Applications Claiming Priority (9)

Application Number	Priority Date	Filing Date	Title
DE4201173.6		1992-01-17
DE4201173A DE4201173C2 (de)	1992-01-17	1992-01-17	Akutarzneimittel in Form von Dihydropyridinderivaten enthaltenden Pellets und ihre Herstellung
DE4201179.5		1992-01-17
DE4201179A DE4201179A1 (de)	1992-01-17	1992-01-17	Wirkstoff(e) enthaltendes granulat oder pellet mit einem geruest aus hydrophilen makromolekuelen und verfahren zu seiner herstellung
US07/876,877 US5384129A (en)	1992-01-17	1992-04-30	Pellets containing dihydropyridine derivatives process for the production thereof and use as rapid action dosage in heart and circulatory diseases
US876.864		1992-04-30
US07/876,864 US5405616A (en)	1992-01-17	1992-04-30	Means for containing active substances, having a shell of hydrophilic macromolecules, active substances and process for preparation thereof
US876.877		1992-04-30
PCT/DE1993/000038 WO1993013757A1 (fr)	1992-01-17	1993-01-18	Corps solides renfermant une matiere active, a structure composee de macromolecules hydrophiles, et leur procede de fabrication

Publications (1)

Publication Number	Publication Date
JPH07502736A true JPH07502736A (ja)	1995-03-23

Family

ID=27435369

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP5512079A Pending JPH07502736A (ja)	1992-01-17	1993-01-18	親水性巨大分子からなる骨格を有する作用物質含有固形物およびその調製法

Country Status (10)

Country	Link
EP (2)	EP0701815B1 (fr)
JP (1)	JPH07502736A (fr)
AT (2)	ATE142484T1 (fr)
AU (1)	AU679906B2 (fr)
CA (1)	CA2128244C (fr)
DE (2)	DE59303759C5 (fr)
DK (2)	DK0621777T3 (fr)
ES (2)	ES2092808T3 (fr)
GR (2)	GR3021223T3 (fr)
WO (1)	WO1993013757A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2006504799A (ja) *	2002-10-16	2006-02-09	ドクトルズベラックスキンウントヘルスケアアクチェンゲゼルシャフト	形成物の身体表面への利用法
JP2008546830A (ja) *	2005-06-28	2008-12-25	サノフイ−アベンテイス	ｐＨ依存性の溶解度を有する有効成分の持続放出製剤

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2714575B1 (fr) *	1994-01-03	1996-02-02	Rhone Poulenc Nutrition Animal	Nouveaux granulés contenant des organismes vivant pour l'alimentation animale.
SE9704401D0 (sv)	1997-11-28	1997-11-28	Astra Ab	Matrix pellets for greasy, oily or sticky drug substances
US7169889B1 (en)	1999-06-19	2007-01-30	Biocon Limited	Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US6867183B2 (en)	2001-02-15	2005-03-15	Nobex Corporation	Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7060675B2 (en)	2001-02-15	2006-06-13	Nobex Corporation	Methods of treating diabetes mellitus
ES2238353T3 (es) *	2001-03-22	2005-09-01	Cognis Ip Management Gmbh	Microcapsulas.
US6828305B2 (en)	2001-06-04	2004-12-07	Nobex Corporation	Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en)	2001-06-04	2004-12-07	Nobex Corporation	Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en)	2001-06-04	2004-03-30	Nobex Corporation	Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en)	2001-06-04	2004-12-28	Nobex Corporation	Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6858580B2 (en)	2001-06-04	2005-02-22	Nobex Corporation	Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en)	2001-06-04	2010-05-11	Biocon Limited	Calcitonin drug-oligomer conjugates, and uses thereof
US7166571B2 (en)	2001-09-07	2007-01-23	Biocon Limited	Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6913903B2 (en)	2001-09-07	2005-07-05	Nobex Corporation	Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7196059B2 (en)	2001-09-07	2007-03-27	Biocon Limited	Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7312192B2 (en)	2001-09-07	2007-12-25	Biocon Limited	Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
WO2003105768A2 (fr)	2002-06-13	2003-12-24	Nobex Corporation	Methodes de reduction du nombre et de la gravite des episodes hypoglycemiques dans le traitement du diabete sucre
FR2843301B1 (fr) *	2002-08-09	2004-10-22	Centre Nat Rech Scient	Forme galenique pour la delivrance colique de principes actifs
FR2843302B1 (fr)	2002-08-09	2004-10-22	Centre Nat Rech Scient	Forme galenique pour la delivrance colique de principes actifs
US9107804B2 (en)	2002-12-10	2015-08-18	Nortec Development Associates, Inc.	Method of preparing biologically active formulations
US7875700B2 (en)	2004-07-19	2011-01-25	Biocon Limited	Cation complexes of insulin compound conjugates, formulation and uses thereof
CA2664315C (fr)	2006-09-15	2016-01-19	Echo Pharmaceuticals B.V.	Unite posologique pour administration sublinguale, buccale ou orale de substances actives pharmaceutiques insolubles dans l'eau
WO2008033023A2 (fr) *	2006-09-15	2008-03-20	Echo Pharmaceuticals B.V.	Granulat contenant une substance pharmaceutiquement active et procédé de fabrication
US8273376B2 (en)	2006-11-17	2012-09-25	Da Volterra	Colonic delivery of metallo-dependent enzymes
EP2243470A1 (fr)	2009-04-22	2010-10-27	Dr. Suwelack Skin & Health Care AG	Corps de formage revêtu lyophilisé
AU2013296803B2 (en) *	2012-08-01	2018-03-08	Eric Ostertag	Free flowing, frozen compositions comprising a therapeutic agent
ITMI20122145A1 (it) *	2012-12-14	2014-06-15	Velleja Res Srl	Composizioni per uso orale contenenti idrolizzati di collagene, di elastina e vitamina c favorenti la deposizione di matrice extra-cellulare
LU102656B1 (de)	2021-03-11	2022-09-12	Prosecur Gmbh	Flüssiges Nahrungsergänzungsmittel zur Immunstimulation, Verfahren zu dessen Herstellung sowie Verwendung

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1248863B (fr) *	1959-01-30
GB887901A (fr) *	1960-04-13	1900-01-01
IE53696B1 (en) *	1981-12-02	1989-01-18	Wyeth John & Brother Ltd	Solid shaped articles
DE3486029T2 (de) *	1983-10-14	1993-05-13	Sumitomo Pharma	Ifn-praeparat mit verzoegerter abgabe fuer parentale verabreichung.
US4837285A (en) *	1984-03-27	1989-06-06	Medimatrix	Collagen matrix beads for soft tissue repair
US4642903A (en) *	1985-03-26	1987-02-17	R. P. Scherer Corporation	Freeze-dried foam dosage form
FR2634121B1 (fr) *	1988-07-13	1992-05-07	Imedex	Procede de preparation de microparticules de collagene et produits obtenus
JPH02135052A (ja) *	1988-11-17	1990-05-23	Taiyo Kagaku Co Ltd	粒状食品の製造方法
US5007790A (en) *	1989-04-11	1991-04-16	Depomed Systems, Inc.	Sustained-release oral drug dosage form
FR2650502B1 (fr) *	1989-08-07	1994-05-27	Delagrange Laboratoires	Nouvelle forme galenique orale ameliorant la biodisponibilite
US5079018A (en) *	1989-08-14	1992-01-07	Neophore Technologies, Inc.	Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
US5215756A (en) *	1989-12-22	1993-06-01	Gole Dilip J	Preparation of pharmaceutical and other matrix systems by solid-state dissolution
ES2102637T3 (es)	1992-01-17	1997-08-01	Alfatec Pharma Gmbh	Cuerpos moldeados criogranulados que contienen un extracto de sustancias vegetales activas y su utilizacion farmaceutica o cosmetica.
ES2108258T3 (es)	1992-01-17	1997-12-16	Alfatec Pharma Gmbh	Granulos que contienen sustancias medicamentosas peptidicas y su preparacion asi como su empleo.
ES2083846T3 (es)	1992-01-17	1996-04-16	Alfatec Pharma Gmbh	Procedimiento para fabricar capsulas de gelatina blanda por un procedimiento de goteo.
DE4221880A1 (de) *	1992-07-03	1994-01-05	Alfatec Pharma Gmbh	Feste und flüssige Lösungen von schwer wasserlöslichen Arzneistoffen

1993
- 1993-01-18 DE DE59303759T patent/DE59303759C5/de not_active Expired - Lifetime
- 1993-01-18 EP EP95113398A patent/EP0701815B1/fr not_active Expired - Lifetime
- 1993-01-18 ES ES93902034T patent/ES2092808T3/es not_active Expired - Lifetime
- 1993-01-18 DE DE59309678T patent/DE59309678D1/de not_active Expired - Fee Related
- 1993-01-18 DK DK93902034.3T patent/DK0621777T3/da active
- 1993-01-18 AT AT93902034T patent/ATE142484T1/de not_active IP Right Cessation
- 1993-01-18 CA CA002128244A patent/CA2128244C/fr not_active Expired - Fee Related
- 1993-01-18 ES ES95113398T patent/ES2133633T3/es not_active Expired - Lifetime
- 1993-01-18 DK DK95113398T patent/DK0701815T3/da active
- 1993-01-18 EP EP93902034A patent/EP0621777B1/fr not_active Expired - Lifetime
- 1993-01-18 JP JP5512079A patent/JPH07502736A/ja active Pending
- 1993-01-18 WO PCT/DE1993/000038 patent/WO1993013757A1/fr active IP Right Grant
- 1993-01-18 AT AT95113398T patent/ATE181666T1/de not_active IP Right Cessation
- 1993-01-18 AU AU33432/93A patent/AU679906B2/en not_active Ceased
1996
- 1996-10-02 GR GR960402577T patent/GR3021223T3/el unknown
1999
- 1999-07-01 GR GR990401751T patent/GR3030675T3/el unknown

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2006504799A (ja) *	2002-10-16	2006-02-09	ドクトルズベラックスキンウントヘルスケアアクチェンゲゼルシャフト	形成物の身体表面への利用法
JP2010280704A (ja) *	2002-10-16	2010-12-16	Dr Suwelack Skin & Health Care Ag	身体表面へ適用する形成物及びその製造方法
JP2013173780A (ja) *	2002-10-16	2013-09-05	Medskin Solutions Dr Suwelack Ag	身体表面へ適用する形成物及びその調製方法
JP2008546830A (ja) *	2005-06-28	2008-12-25	サノフイ−アベンテイス	ｐＨ依存性の溶解度を有する有効成分の持続放出製剤

Also Published As

Publication number	Publication date
DK0701815T3 (da)	2000-02-07
GR3021223T3 (en)	1997-01-31
DE59303759C5 (de)	2009-04-09
CA2128244A1 (fr)	1993-07-22
ATE181666T1 (de)	1999-07-15
AU3343293A (en)	1993-08-03
GR3030675T3 (en)	1999-11-30
DK0621777T3 (da)	1996-10-21
ATE142484T1 (de)	1996-09-15
CA2128244C (fr)	1998-09-22
ES2133633T3 (es)	1999-09-16
EP0701815B1 (fr)	1999-06-30
WO1993013757A1 (fr)	1993-07-22
AU679906B2 (en)	1997-07-17
EP0621777B1 (fr)	1996-09-11
DE59309678D1 (de)	1999-08-05
ES2092808T3 (es)	1996-12-01
EP0621777A1 (fr)	1994-11-02
EP0701815A1 (fr)	1996-03-20
DE59303759D1 (de)	1996-10-17

Publication	Publication Date	Title
JPH07502736A (ja)	1995-03-23	親水性巨大分子からなる骨格を有する作用物質含有固形物およびその調製法
US5876754A (en)	1999-03-02	Solid bodies containing active substances and a structure consisting of hydrophilic macromolecules, plus a method of producing such bodies
US5405616A (en)	1995-04-11	Means for containing active substances, having a shell of hydrophilic macromolecules, active substances and process for preparation thereof
JP4943581B2 (ja)	2012-05-30	迅速分散性固形経口投与用剤形の製造方法
KR0146960B1 (ko)	1998-08-17	마이크로-입자 또는 나노-입자로 구성된 신규한 고체 다공성 단위체 및 그것의 제조방법
EP0642334B1 (fr)	1999-08-18	Presentations pharmaceutiques et autres formes galeniques
JP2975112B2 (ja)	1999-11-10	控えめな水溶性をもつ医薬物質の固体及び液体溶液
US5738875A (en)	1998-04-14	Process for preparing solid pharmaceutical dosage forms
CN100531724C (zh)	2009-08-26	双相释放药理活性物质或其它物质的薄膜形制剂
JP3233638B2 (ja)	2001-11-26	凍結乾燥された薬投与形状物の製造方法
JPH0457643B2 (fr)	1992-09-14
JPS63112513A (ja)	1988-05-17	スプレードライしたアセトアミノフェン
RO122011B1 (ro)	2008-11-28	Compoziţii farmaceutice cu dispersare rapidă
WO2002047607A2 (fr)	2002-06-20	Procede de preparation d'une forme posologique rapidement soluble
WO1988006457A1 (fr)	1988-09-07	Composition medicinale contenant de l'albumine en tant que support et procede de preparation
US5837287A (en)	1998-11-17	Process for preparing solid pharmaceutical dosage forms
Parashar et al.	2012	Fast dissolving tablet
CA2128242C (fr)	1998-09-22	Articles moulees, en particulier des pastilles, renfermant un ou plusieurs extrait(s) de vegetaux, et utilisation pharmaceutique ou cosmetique de ces granules
WO2005079750A2 (fr)	2005-09-01	Pellicules pour formes posologiques
JPH07502912A (ja)	1995-03-30	滴下法にもとづき軟質ゼラチンカプセルを製造する方法
JP4944327B2 (ja)	2012-05-30	急速に崩壊するキトサンを原料とするペレット
Sharma et al.	2010	Fast Dissolving Tablets-A Review and Recent Advances in Manufacturing Technologies
AU677198C (en)	1997-12-04	Pharmaceutical and other dosage forms
JPH04210912A (ja)	1992-08-03	ビーズ及びその調製物を含む固体多孔質単位剤形
HK1010693B (en)	2000-04-20	Pharmaceutical and other dosage forms